secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001193125-23-281574
Event type: leadership
Sentiment:  negative
Materiality: 0.45
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Pharma EVP R&D Doug Williamson to depart; search for replacement underway
--------------------------------------------------------------------------------

- Doug Williamson, MD, EVP Head of R&D, leaving Acadia to pursue other opportunities.
- Williamson joined Acadia in January 2023 and will remain during a transitional period.
- Company has initiated a search for a replacement EVP of Research and Development.
- No financial impact or guidance changes disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312523281574/0001193125-23-281574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312523281574/d586090d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-281574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer